ALK and non-small cell lung carcinoma: The list has been revised every few years since it was first reported, and DS-GPA for NSCLC was redefined as Lung-molGPA in 2017, with an adjustment for the findings that patients with gene alteration of epidermal growth factor receptor (EGFR) and/or anaplastic lymphoma kinase (ALK) exhibited favorable prognosis [7].